Affinity Asset Advisors LLC Sells 10,000 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA)

Affinity Asset Advisors LLC lowered its stake in Vera Therapeutics, Inc. (NASDAQ:VERA) by 2.3% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 425,000 shares of the company’s stock after selling 10,000 shares during the period. Vera Therapeutics makes up approximately 2.4% of Affinity Asset Advisors LLC’s holdings, making the stock its 13th largest holding. Affinity Asset Advisors LLC’s holdings in Vera Therapeutics were worth $17,973,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. SG Americas Securities LLC lifted its holdings in Vera Therapeutics by 116.7% in the 4th quarter. SG Americas Securities LLC now owns 20,270 shares of the company’s stock worth $857,000 after buying an additional 10,916 shares during the period. Lord Abbett & CO. LLC boosted its holdings in Vera Therapeutics by 41.1% in the third quarter. Lord Abbett & CO. LLC now owns 426,014 shares of the company’s stock worth $18,830,000 after acquiring an additional 124,197 shares in the last quarter. Barclays PLC grew its stake in shares of Vera Therapeutics by 94.1% in the third quarter. Barclays PLC now owns 85,395 shares of the company’s stock worth $3,774,000 after acquiring an additional 41,394 shares during the last quarter. Geode Capital Management LLC raised its position in shares of Vera Therapeutics by 2.1% in the 3rd quarter. Geode Capital Management LLC now owns 1,004,665 shares of the company’s stock worth $44,415,000 after purchasing an additional 20,223 shares during the last quarter. Finally, Raymond James Financial Inc. bought a new position in Vera Therapeutics in the 4th quarter worth about $2,948,000. 99.21% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of research firms have weighed in on VERA. The Goldman Sachs Group initiated coverage on shares of Vera Therapeutics in a research note on Tuesday, January 28th. They set a “buy” rating and a $58.00 price objective for the company. Wolfe Research started coverage on shares of Vera Therapeutics in a report on Tuesday, February 4th. They issued an “outperform” rating and a $49.00 price objective for the company. Guggenheim lifted their target price on Vera Therapeutics from $59.00 to $61.00 and gave the stock a “buy” rating in a report on Thursday, February 27th. Finally, JPMorgan Chase & Co. dropped their price objective on Vera Therapeutics from $77.00 to $71.00 and set an “overweight” rating on the stock in a research report on Tuesday, March 4th. One analyst has rated the stock with a hold rating, six have given a buy rating and three have assigned a strong buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $64.67.

Vera Therapeutics Price Performance

NASDAQ:VERA opened at $21.50 on Tuesday. The business’s 50-day simple moving average is $27.25 and its two-hundred day simple moving average is $37.06. Vera Therapeutics, Inc. has a 52 week low of $18.53 and a 52 week high of $51.61. The stock has a market cap of $1.37 billion, a PE ratio of -8.24 and a beta of 1.28. The company has a quick ratio of 13.76, a current ratio of 13.76 and a debt-to-equity ratio of 0.17.

Vera Therapeutics (NASDAQ:VERA) last issued its earnings results on Wednesday, February 26th. The company reported ($0.72) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.83) by $0.11. As a group, analysts forecast that Vera Therapeutics, Inc. will post -2.89 EPS for the current fiscal year.

About Vera Therapeutics

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.